Netherlands· NL-10c688f68061
AJOVY 225 mg, oplossing voor injectie in voorgevulde pen
A fremanezumab product containing fremanezumab, registered in Netherlands by Teva GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Fremanezumab is registered in 15 of 19 countries.
Countries holding a registration under ATC N02CD03 (fremanezumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Fremanezumab · ATC N02CD03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FREMANEZUMAB
- Manufacturer
- Teva GmbH
- Country
- Netherlands (NL)
- ATC code
- N02CD03
- ATC class
- Fremanezumab
- Defined daily dose
- 7.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/19/1358
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fremanezumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceAJOVY 225 mg, solution injectable en seringue préremplieTEVA (ALLEMAGNE)
- IrelandAJOVY 225 mg Solution for injectionTEVA GmbH
- CzechiaAJOVYTeva GmbH, Ulm
- United StatesAJOVYTeva Pharmaceuticals USA, Inc.
- SwitzerlandAjovy
- FinlandAJOVYTeva GmbH
- United KingdomAjovy 225mg/1.5ml solution for injection pre-filled pensTeva UK Ltd
- BelgiumAjovy 225 mgTeva
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ajovy
- Iceland · Ajovy
- Liechtenstein · Ajovy
- Norway · Ajovy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/35b69244-c7ff-42f4-9bfe-618a5b7fc58d GET /v1/drugs/35b69244-c7ff-42f4-9bfe-618a5b7fc58d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Fremanezumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129303",
"excipients": [
"DINATRIUMEDETAAT 2-WATER",
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLYSORBAAT 80 (E 433)",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"FREMANEZUMAB"
],
"leaflet_url": null,
"authorised_at": "2019/03/28",
"procedure_number": "EMEA/H/C/004833",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/19/1358",
"additional_monitoring": "N"
}See everything about fremanezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.